Form 4: Processa Pharmaceuticals Grants Significant Equity to Chief Business Strategy Officer

Processa Pharmaceuticals, Inc. has granted 1,401,650 Restricted Stock Units to Chief Business Strategy Officer Patrick Lin, with a substantial portion contingent on stockholder approval.

Summary

• Patrick Lin, the Chief Business Strategy Officer of Processa Pharmaceuticals, Inc. (PCSA), was granted 1,401,650 Restricted Stock Units (RSUs) on July 24, 2025.
• These RSUs were granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan.
• A significant portion, 1,384,411 shares, of the granted RSUs are subject to stockholder approval of the revised Omnibus Plan.
• Each RSU represents a contingent right to receive one share of Processa Pharmaceuticals' common stock.
• The RSUs will vest in a staggered schedule: one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.
• Following this transaction, Patrick Lin beneficially owns a total of 1,412,082 derivative securities, which includes the newly acquired RSUs and previously held derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as it indicates alignment of management's interests with shareholders and serves as a retention tool. The contingency of stockholder approval for a large portion of the grant introduces a minor element of uncertainty, preventing a higher score.

Positives

• The grant of a substantial number of Restricted Stock Units to a key executive like the Chief Business Strategy Officer helps align management's long-term interests with those of the shareholders.
• Equity grants serve as a strong retention incentive for key personnel, encouraging continued dedication to the company's success.

Negatives

• A significant portion of the RSU grant (1,384,411 shares out of 1,401,650) is contingent on stockholder approval of the revised Omnibus Plan, introducing a potential uncertainty.
• The eventual vesting and conversion of these RSUs into common stock will result in dilution for existing shareholders.

Risks

• The grant of 1,384,411 Restricted Stock Units is subject to stockholder approval of the revised Omnibus Plan, meaning a portion of the grant may not materialize if approval is not obtained.
• Future dilution of common stock upon the vesting and conversion of the 1,401,650 Restricted Stock Units.

Future Outlook

The grant of these Restricted Stock Units indicates a strategy to incentivize and retain key management over the long term, aligning their performance with the company's future growth and shareholder value creation through a multi-year vesting schedule.

Management Comments

• The grant of Restricted Stock Units under the 2019 Omnibus Incentive Plan reflects the company's commitment to using equity-based compensation to attract, retain, and motivate key executives.

Industry Context

The use of Restricted Stock Units as a form of executive compensation is a common practice across various industries, particularly in biotechnology and pharmaceuticals, where long-term incentives are crucial for retaining talent and aligning interests in a research and development-intensive environment.

Comparison to Industry Standards

• While the grant of Restricted Stock Units is a standard practice for executive compensation across industries, this filing does not provide specific details or benchmarks for direct comparison to other companies or projects within the pharmaceutical sector regarding the size of the grant relative to company valuation or executive role.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting of RSUs, but also benefit from increased alignment of executive interests with long-term company performance.
• Employees: The grant is part of the company's incentive plan, which can positively impact overall employee morale and retention strategies.

Next Steps

• Stockholders will need to approve the revised 2019 Omnibus Incentive Plan for 1,384,411 of the granted Restricted Stock Units to become fully effective.
• The Restricted Stock Units will begin vesting on January 1, 2026, with subsequent monthly vesting until fully vested on January 1, 2028.

Key Dates

Recommendation

The grant of Restricted Stock Units to a key executive is a positive step for aligning management incentives with shareholder interests and retaining talent. However, a significant portion of the grant is subject to future stockholder approval, and the potential for future dilution exists upon vesting. This filing primarily reflects standard executive compensation practices rather than a fundamental change in company outlook, thus a 'hold' recommendation is appropriate.

Keywords

Processa Pharmaceuticals, PCSA, Restricted Stock Units, RSU, equity grant, executive compensation, insider transaction, Form 4, Patrick Lin, Omnibus Incentive Plan, stockholder approval